Regional distribution of cytochrome p450 mRNA expression in the liver and small intestine of cynomolgus monkeys

Drug Metabolism and Pharmacokinetics

Volumn 25, Issue 3, 2010, Pages 290-297

  Nakanishi, Yasuharu ^a   Matsushita, Akinori ^a   Matsuno, Kiyomi ^a   Iwasaki, Kazuhide ^a   Utoh, Masahiro ^a   Nakamura, Chika ^a   Uno, Yasuhiro ^a  

^a SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

Author keywords

Cynomolgus monkey; Cytochrome P450; Liver; mRNA expression; Small intestine

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A; CYTOCHROME P450 2A23; CYTOCHROME P450 2A24; CYTOCHROME P450 2B6; CYTOCHROME P450 2C; CYTOCHROME P450 2C20; CYTOCHROME P450 2C43; CYTOCHROME P450 2C75; CYTOCHROME P450 2C76; CYTOCHROME P450 2D; CYTOCHROME P450 2D17; CYTOCHROME P450 2E1; CYTOCHROME P450 2J2; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; MESSENGER RNA; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DUODENUM; GENE EXPRESSION; ILEUM; JEJUNUM; LIVER; MALE; MONKEY; NONHUMAN; ORTHOLOGY; PROTEIN LOCALIZATION; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL INTESTINE; ANATOMY AND HISTOLOGY; ANIMAL; ENZYMOLOGY; GENETICS; MACACA FASCICULARIS; METABOLISM; PHYSIOLOGY;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; GENE EXPRESSION; INTESTINE, SMALL; LIVER; MACACA FASCICULARIS; MALE;

EID: 77954298784     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.25.290     Document Type: Article

References (52)

1. Iwasaki, K. and Uno, Y.: Cynomolgus monkey CYPs: a comparison with human CYPs. Xenobiotica, 39: 578-581 (2009).
2. Ward, K. W. and Smith, B. R.: A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab. Dispos., 32: 603-611 (2004).
3. Wilkinson, G. R.: Drug metabolism and variability among patients in drug response. N. Engl. J. Med., 352: 2211-2221 (2005).
4. Thummel, K. E. and Wilkinson, G. R.: In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol., 38: 389-430 (1998).
5. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. and Guengerich, F. P.: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270: 414-423 (1994).
6. Paine, M. F., Hart, H. L., Ludington, S. S., Haining, R. L., Rettie, A. E. and Zeldin, D. C.: The human intestinal cytochrome P450 "pie''. Drug Metab. Dispos., 34: 880-886 (2006).
7. Paine, M. F., Khalighi, M., Fisher, J. M., Shen, D. D., Kunze, K. L., Marsh, C. L., Perkins, J. D. and Thummel, K. E.: Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther., 283: 1552-1562 (1997).
8. Watkins, P. B., Wrighton, S. A., Schuetz, E. G., Molowa, D. T. and Guzelian, P. S.: Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J. Clin. Invest., 80: 1029-1036 (1987).
9. de Waziers, I., Cugnenc, P. H., Yang, C. S., Leroux, J. P. and Beaune, P. H.: Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther., 253: 387-394 (1990).
10. Zhang, Q. Y., Dunbar, D., Ostrowska, A., Zeisloft, S., Yang, J. and Kaminsky, L. S.: Characterization of human small intestinal cytochromes P-450. Drug Metab. Dispos., 27: 804-809 (1999).
11. Kolars, J. C., Awni, W. M., Merion, R. M. and Watkins, P. B.: First-pass metabolism of cyclosporin by the gut. Lancet, 338: 1488-1490 (1991).
12. Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., Marsh, C. L., McVicar, J. P., Barr, D. M., Gillies, B. S. and Thummel, K. E.: First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther., 60: 14-24 (1996).
13. von Richter, O., Greiner, B., Fromm, M. F., Fraser, R., Omari, T., Barclay, M. L., Dent, J., Somogyi, A. A. and Eichelbaum, M.: Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clin. Pharmacol. Ther., 70: 217-227 (2001).
14. Lin, J. H. and Lu, A. Y.: Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu. Rev. Pharmacol. Toxicol., 41: 535-567 (2001).
15. Nishimura, T., Amano, N., Kubo, Y., Ono, M., Kato, Y., Fujita, H., Kimura, Y. and Tsuji, A.: Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey. Drug Metab. Dispos., 35: 1275-1284 (2007).
16. Fasco, M. J., Silkworth, J. B., Dunbar, D. A. and Kaminsky, L. S.: Rat small intestinal cytochromes P450 probed by warfarin metabolism. Mol. Pharmacol., 43: 226-233 (1993).
17. Kaminsky, L. S. and Fasco, M. J.: Small intestinal cytochromes P450. Crit. Rev. Toxicol., 21: 407-422 (1991).
18. Zhang, Q. Y., Wikoff, J., Dunbar, D. and Kaminsky, L.: Characterization of rat small intestinal cytochrome P450 composition and inducibility. Drug Metab. Dispos., 24: 322-328 (1996).
19. Mitschke, D., Reichel, A., Fricker, G. and Moenning, U.: Characterization of cytochrome P450 protein expression along the entire length of the intestine of male and female rats. Drug Metab. Dispos., 36: 1039-1045 (2008).
20. Lin, Y. S., Dowling, A. L., Quigley, S. D., Farin, F.M., Zhang, J., Lamba, J., Schuetz, E. G. and Thummel, K. E.: Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol. Pharmacol., 62: 162-172 (2002).
21. Uno, Y., Fujino, H., Kito, G., Kamataki, T. and Nagata, R.: CYP2C76, a novel cytochrome P450 in cynomolgus monkey, is a major CYP2C in liver, metabolizing tolbutamide and testosterone. Mol. Pharmacol., 70: 477-486 (2006).
22. Uno, Y., Hosaka, S., Matsuno, K., Nakamura, C., Kito, G., Kamataki, T. and Nagata, R.: Characterization of cynomolgus monkey cytochrome P450 (CYP) cDNAs: Is CYP2C76 the only monkey-specific CYP gene responsible for species differences in drug metabolism? Arch. Biochem. Biophys., 466: 98-105 (2007).
23. Nishimura, M., Koeda, A., Morikawa, H., Satoh, T., Narimatsu, S. and Naito, S.: Tissue-specific mRNA expression profiles of drug-metabolizing enzymes and transporters in the cynomolgus monkey. Drug Metab. Pharmacokinet., 24: 139-144 (2009).
24. Bieàche, I., Narjoz, C., Asselah, T., Vacher, S., Marcellin, P., Lidereau, R., Beaune, P. and de Waziers, I.: Reverse transcriptase- PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet. Genomics, 17: 731-742 (2007).
25. Andersen, M. R., Farin, F.M. and Omiecinski, C. J.: Quantification of multiple human cytochrome P450 mRNA molecules using competitive reverse transcriptase-PCR. DNA Cell Biol., 17: 231-238 (1998).
26. Choudhary, D., Jansson, I., Stoilov, I., Sarfarazi, M. and Schenkman, J. B.: Expression patterns of mouse and human CYP orthologs (families 1-4) during development and in different adult tissues. Arch. Biochem. Biophys., 436: 50-61 (2005).
27. Nishimura, M., Yaguti, H., Yoshitsugu, H., Naito, S. and Satoh, T.: Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi, 123: 369-375 (2003).
28. Sumida, A., Kinoshita, K., Fukuda, T., Matsuda, H., Yamamoto, I., Inaba, T. and Azuma, J.: Relationship between mRNA levels quantified by reverse transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2E1 in human liver. Biochem. Biophys. Res. Commun., 262: 499-503 (1999).
29. Dogra, S. C., Whitelaw, M. L. and May, B. K.: Transcriptional activation of cytochrome P450 genes by different classes of chemical inducers. Clin. Exp. Pharmacol. Physiol., 25: 1-9 (1998).
30. Gonzalez, F. J., Liu, S. Y. and Yano, M.: Regulation of cytochrome P450 genes: molecular mechanisms. Pharmacogenetics, 3: 51-57 (1993).
31. Sakuma, T., Hieda, M., Igarashi, T., Ohgiya, S., Nagata, R., Nemoto, N. and Kamataki, T.: Molecular cloning and functional analysis of cynomolgus monkey CYP1A2. Biochem. Pharmacol., 56: 131-139 (1998).
32. Bogaards, J. J., Bertrand, M., Jackson, P., Oudshoorn, M. J., Weaver, R. J., van Bladeren, P. J. and Walther, B.: Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica, 30: 1131-1152 (2000).
33. Burke, M. D., Thompson, S., Weaver, R. J., Wolf, C. R. and Mayer, R. T.: Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem. Pharmacol., 48: 923-936 (1994).
34. Lown, K. S., Bailey, D. G., Fontana, R. J., Janardan, S. K., Adair, C. H., Fortlage, L. A., Brown, M. B., Guo, W. and Watkins, P. B.: Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest., 99: 2545-2553 (1997).
35. Paine, M. F., Schmiedlin-Ren, P. and Watkins, P. B.: Cytochrome P-450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole. Drug Metab. Dispos., 27: 360-364 (1999).
36. Windmill, K. F., McKinnon, R. A., Zhu, X., Gaedigk, A., Grant, D. M. and McManus, M. E.: The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Mutat. Res., 376: 153-160 (1997).
37. Wester, M. R., Lasker, J. M., Johnson, E. F. and Raucy, J. L.: CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Drug Metab. Dispos., 28: 354-359 (2000).
38. Lasker, J. M., Wester, M. R., Aramsombatdee, E. and Raucy, J. L.: Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, Smephenytoin, and omeprazole hydroxylations. Arch. Biochem. Biophys., 353: 16-28 (1998).
39. Obach, R. S., Zhang, Q. Y., Dunbar, D. and Kaminsky, L. S.: Metabolic characterization of the major human small intestinal cytochrome p450s. Drug Metab. Dispos., 29: 347-352 (2001).
40. Lin, J. H., Chiba, M. and Baillie, T. A.: Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol. Rev., 51: 135-158 (1999).
41. Thervet, E., Anglicheau, D., King, B., Schlageter, M. H., Cassinat, B., Beaune, P., Legendre, C. and Daly, A. K.: Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation, 76: 1233-1235 (2003).
42. Op den Buijsch, R. A., Christiaans, M. H., Stolk, L. M., de Vries, J. E., Cheung, C. Y., Undre, N. A., van Hooff, J. P., van Dieijen-Visser, M. P. and Bekers, O.: Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam. Clin. Pharmacol., 21: 427-435 (2007).
43. Tsuchiya, N., Satoh, S., Tada, H., Li, Z., Ohyama, C., Sato, K., Suzuki, T., Habuchi, T. and Kato, T.: Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation, 78: 1182-1187 (2004).
44. Zheng, H., Webber, S., Zeevi, A., Schuetz, E., Zhang, J., Bowman, P., Boyle, G., Law, Y., Miller, S., Lamba, J. and Burckart, G. J.: Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am. J. Transplant., 3: 477-483 (2003).
45. Zheng, H., Zeevi, A., Schuetz, E., Lamba, J., McCurry, K., Griffith, B. P., Webber, S., Ristich, J., Dauber, J., Iacono, A., Grgurich, W., Zaldonis, D., McDade, K., Zhang, J. and Burckart, G. J.: Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J. Clin. Pharmacol., 44: 135-140 (2004).
46. Hernandez, R. D., Hubisz, M. J., Wheeler, D. A., Smith, D. G., Ferguson, B., Rogers, J., Nazareth, L., Indap, A., Bourquin, T., McPherson, J., Muzny, D., Gibbs, R., Nielsen, R. and Bustamante, C. D.: Demographic histories and patterns of linkage disequilibrium in Chinese and Indian rhesus macaques. Science, 316: 240-243 (2007).
47. Street, S. L., Kyes, R. C., Grant, R. and Ferguson, B.: Single nucleotide polymorphisms (SNPs) are highly conserved in rhesus (Macaca mulatta) and cynomolgus (Macaca fascicularis) macaques. BMC Genomics, 8: 480 (2007).
48. Ferguson, B., Street, S. L., Wright, H., Pearson, C., Jia, Y., Thompson, S. L., Allibone, P., Dubay, C. J., Spindel, E. and Norgren, R. B., Jr.: Single nucleotide polymorphisms (SNPs) distinguish Indian-origin and Chinese-origin rhesus macaques (Macaca mulatta). BMC Genomics, 8: 43 (2007).
49. Uno, Y., Sakuraba, H., Uehara, S., Kumano, T., Matsuno, K., Nakamura, C., Kito, G., Kamataki, T. and Nagata, R.: A null allele impairs function of CYP2C76 gene in cynomolgus monkeys: a possible genetic tool for generation of a better animal model in drug metabolism. Drug Metab. Dispos., 37: 14-17 (2009).
50. Uno, Y., Matsushita, A., Osada, N., Uehara, S., Kohara, S., Nagata, R., Fukuzaki, K., Utoh, M., Murayama, N. and Yamazaki, H.: Genetic variants of CYP3A4 and CYP3A5 in cynomolgus and rhesus macaques. Drug Metab. Dispos., 38: 209-214 (2010).
51. Westlind-Johnsson, A., Malmebo, S., Johansson, A., Otter, C., Andersson, T. B., Johansson, I., Edwards, R. J., Boobis, A. R. and Ingelman-Sundberg, M.: Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab. Dispos., 31: 755-761 (2003).
52. Koch, I., Weil, R., Wolbold, R., Brockmoäller, J., Hustert, E., Burk, O., Nuessler, A., Neuhaus, P., Eichelbaum, M., Zanger, U. and Wojnowski, L.: Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab. Dispos., 30: 1108-1114 (2002).